Fecal Molecular Susceptibility-guided Hp Rescue Therapy
Key facts
- Who runs it
- Shanghai Zhongshan Hospital
- Where
- China4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 290 people, planned
- Started
- 28 Feb 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 7-day fecal molecular susceptibility-guided therapy
- 14-day fecal molecular susceptibility-guided therapy
- Record updated
- 12 February 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Voluntarily participate in this clinical study; fully understand, be informed about this study, and sign the Informed Consent Form (ICF)
- Age between 18 and 75 years (inclusive) on the day of signing the ICF
- 13C-urea breath test (13C-UBT) and fecal HP nucleic acid detection confirming Helicobacter pylori (Hp) infection
- previously eradicated HP
Who cannot take part
- Alcohol and/or drug abuse (dependence or addiction) or individuals judged by the physician to have poor compliance
- Use of antibiotics, bismuth-containing drugs, PPIs, or traditional Chinese medicines within 4 weeks before treatment
- Individuals with a known allergy to the medication
- Patients with severe cardiovascular, pulmonary, renal, hepatic, hematologic, neurologic, endocrine, or psychiatric disorders
- Any condition deemed by the investigator to be unsuitable for enrollment
- Participants or guardians who refuse to enroll
- Pregnant or lactating women
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the eradication efficacy and health economic benefits of individualized regimens guided by fecal molecular susceptibility testing with 7-day and 14-day courses in the rescue treatment of Helicobacter pylori infection. The main questions it aims to answer are:
Read full original descriptionShow less
1. What is the H. pylori eradication rate of the 7-day versus 14-day individualized regimens? 2. What are the safety, adherence, and cost-effectiveness of the 7-day versus 14-day individualized regimens? Researchers will compare the 7-day course group and the 14-day course group to see if the 7-day course is non-inferior to the 14-day course in terms of eradication rate.
Participants will:
1. Undergo fecal H. pylori drug resistance gene testing 2. Receive randomized assignment to either 7-day or 14-day individualized treatment based on drug susceptibility results 3. Complete follow-up visits at 1 week and 4-8 weeks after stopping treatment for adverse event monitoring and 13C-urea breath test
The 2 groups in the trial
- 7-dayTreatment being tested
7-day fecal molecular susceptibility-guided therapy
Treatment: 7-day fecal molecular susceptibility-guided therapy
- 14-dayExisting treatment, for comparison
14-day fecal molecular susceptibility-guided therapy
Treatment: 14-day fecal molecular susceptibility-guided therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Efficacy and Health Economic Evaluation of Fecal Molecular Susceptibility-guided Therapy for Helicobacter Pylori Infection Rescue Treatment: Multicenter Randomized Controlled Study
- Criteria questions
- Built from NCT07405697, who can take part
- Record updated
- 12 February 2026